Related by context. All words. (Click for frequent words.) 62 EGFR mutation status 61 Kalantar Zadeh 61 K ras mutations 61 relapsed ALL 61 elacytarabine 61 CYP#D# genotype 61 HER2 expression 60 kidney allograft 60 Eric Van Cutsem 60 TroVax ® 60 Zheng Cui 60 prostate cancer CaP 60 PITX2 methylation 60 CC genotype 60 BEXXAR Therapeutic Regimen 60 Kantarjian 60 mutated K ras 60 operable breast cancer 59 relapsed SCLC 59 Hedgehog inhibitor 59 pCR 59 K ras mutation 59 Randomized clinical trials 59 imatinib therapy 59 Subgroup analysis 59 ER CHOP 59 liver metastasis 59 BRCA mutation carriers 59 Cristofanilli 59 complete cytogenetic response 58 coinfected patients 58 hepatic fibrosis 58 pancreatic adenocarcinoma 58 Bresalier 58 medically inoperable 58 prostate cancer CRPC 58 HSCT 58 Weimbs 58 gp# vaccine 58 antiretroviral naïve 58 peritoneal carcinomatosis 58 relapsed AML 58 Laheru 58 autologous transplants 58 intracerebral haemorrhage 58 virological response 58 Singh Manoux 58 stratifying patients 58 glycated hemoglobin levels 58 relapsed ovarian cancer 58 EGFR mutation positive 58 nonischemic 58 Wadih Arap 58 LV dysfunction 58 visceral metastases 58 HIV HCV coinfected 58 T#I [002] 57 hormone refractory 57 tumor histology 57 nonalcoholic steatohepatitis NASH 57 pharmacologic intervention 57 resected pancreatic cancer 57 BRAF V#E mutation 57 prognostic indicators 57 KRAS mutation 57 Boden Albala 57 PRIMO CABG 57 genotypic resistance 57 CINQUIL 57 perioperatively 57 Dr. Gambotto 57 ADVEXIN therapy 57 elective PCI 57 Tony Wyss Coray 57 HBeAg 57 attain statistical significance 57 Lisa N. Drakeman 57 preoperative chemotherapy 57 Ele Ferrannini 57 biochemical relapse 57 nonmetastatic 57 riociguat 57 HuMax EGFr 57 ADAGIO study 57 sustained virological response 57 CR nPR 57 de novo AML 57 Subgroup analyzes 57 Ben Slotman 57 Schunkert 57 completely resected 57 Dr. Cassian Yee 57 Bengt Winblad 57 thrombocytopenic 56 testosterone supplementation 56 clinically meaningful improvement 56 mRCC 56 diabetic kidney 56 IRX 2 56 axitinib 56 prognostic variables 56 T2DM 56 ELACYT 56 perioperative complications 56 Prognostic factors 56 ABSORB trial 56 underwent resection 56 oral FTY# 56 TNF blocker therapy 56 Marambaud 56 ImmunoVEX HSV2 56 CALGB 56 metastatic lung cancer 56 HER2 positive cancers 56 BRAF mutation 56 prostate carcinoma 56 NMIBC 56 prospectively defined 56 relapsed MM 56 smoldering multiple myeloma 56 CTAP# Capsules 56 Alessandro Riva 56 Oliver Sartor 56 heavily pretreated 56 Doxil ® 56 Eliezer Zomer Ph.D. 56 Laura Mauri 56 recurrent glioblastoma 56 hepatorenal syndrome 56 refractory colorectal cancer 56 metastatic renal cell 56 everolimus eluting stents 56 castration resistant prostate cancer 56 farletuzumab 56 Frobell 56 Ceflatonin 56 unresectable tumors 56 oncologic outcomes 56 ovarian carcinoma 56 Paavonen 56 Virulizin ® 56 GRN# 56 Symadex 56 Lung transplantation 56 mCRC patients 56 immune reconstitution 56 T1DM 56 symptomatic carotid stenosis 56 Oncotype 56 decitabine 56 echocardiographic parameters 56 cranial radiation 56 Pharmacokinetics PK 56 galiximab 56 gefitinib Iressa 56 troponin T 56 hsCRP levels 56 hematological parameters 56 chronic myocardial ischemia 56 Di Bisceglie 56 smoldering myeloma 56 olaparib 56 metastatic renal cell carcinoma 56 Matchar 56 metastatic RCC 56 Qi Dai 56 Naresh Punjabi 56 EDEMA3 trial 56 pretransplant 56 invasive candidiasis 56 alvespimycin 56 metastatic gastric 56 multivariate Cox 55 EpCAM expression 55 hematological malignancy 55 tamoxifen therapy 55 MAGE A3 55 postoperative radiotherapy 55 liposomal amphotericin B 55 methylation markers 55 postoperative chemotherapy 55 recurrent glioblastoma multiforme 55 NSCL cancer 55 HORIZONS AMI trial 55 sunitinib 55 KRAS mutant tumors 55 Acute Coronary Syndromes ACS 55 EchoCRT 55 PROSTVAC ® 55 Wischik 55 cytoreductive surgery 55 chronic granulomatous disease 55 HER2 positive metastatic breast 55 antiretroviral naive 55 FLT3 55 CMV infections 55 Piccart 55 CR# vcMMAE 55 breast cancer subtypes 55 intracranial stenosis 55 bronchopulmonary dysplasia BPD 55 MYDICAR 55 GIST tumors 55 Treg cell 55 adjuvant tamoxifen 55 cMET 55 IFN beta 55 HER2 overexpression 55 interferon beta therapy 55 tumor recurrence 55 thromboprophylaxis 55 Vojo Vukovic MD Ph.D. 55 colorectal carcinoma 55 antiangiogenic therapy 55 perioperative morbidity 55 virological suppression 55 iPTH 55 prognostic markers 55 ICD implantation 55 Bergenstal 55 adjuvant colon cancer 55 angiographically 55 Robert Siliciano 55 PITX2 55 predictive biomarker 55 Kaplan Meier analysis 55 unresectable stage 55 Getzenberg 55 K RAS 55 methotrexate therapy 55 bladder carcinoma 55 antioxidant supplementation 55 DAPT 55 OnDose TM 55 lung metastasis 55 IDH mutations 55 Ascherio 55 pharmacodynamic properties 55 Alastair Compston 55 nodal metastasis 55 5q deletion 55 oblimersen 55 elevated CRP 55 MAGE A3 ASCI 55 refractory metastatic 55 STRIDE PD 55 Stefan Willich 55 metastatic castration resistant 55 β blockers 55 trastuzumab Herceptin ® 55 bronchopulmonary dysplasia 55 CSF biomarkers 55 KRAS mutations 55 B7 H3 55 Zevalin consolidation 55 Myelodysplastic Syndrome MDS 55 EGFR mutation 55 cytogenic 55 R0 resection 55 HYVET 55 haematological cancers 55 IL#B 55 minimally symptomatic 55 atherothrombosis 55 chromosomal mutations 55 posttransplant 55 invasive lobular carcinoma 55 genomic biomarker 55 prostate carcinogenesis 55 Roman Hovorka 55 Adjuvant chemotherapy 55 immunosuppressant therapies 55 pomalidomide 55 chronic myeloid 55 gastric carcinoma 55 HbA 1c levels 55 Kandzari 55 Montalescot 55 arterial thickening 55 RE LY trial 55 registrational trial 55 Hepatocellular Carcinoma HCC 55 motesanib 55 pain palliation 55 pegylated liposomal doxorubicin 55 abnormal glucose metabolism 55 imatinib resistance 55 virologic failure 55 Haptoglobin 55 debulking surgery 55 liver metastases 54 biliary tract cancer 54 familial hypercholesterolemia 54 prospectively stratified 54 fluoropyrimidine 54 Robert Zivadinov 54 inherited predisposition 54 BARI 2D 54 histologic subtype 54 overt hypothyroidism 54 ALI ARDS 54 Karlseder 54 nucleoside naive patients 54 adjuvant radiation 54 pelvic lymphadenectomy 54 progression TTP 54 nonfasting triglyceride levels 54 euthymic patients 54 SYNTAX trial 54 cystinosis patients 54 KRAS oncogene 54 MDS AML 54 prescribe statins 54 HCV infected 54 QTc prolongation 54 hematopoietic cancers 54 E. Magnus Ohman 54 intensive statin therapy 54 canakinumab 54 malignant transformation 54 #F FDG PET 54 PlGF 54 FOLFOX4 54 metastatic malignant 54 phase IIb study 54 Pier Paolo Pandolfi 54 MELD score 54 locoregional disease 54 Lynda Chin 54 neurologic progression 54 PROSTVAC VF 54 kinase inhibition 54 PCNSL 54 Surgical resection 54 warfarin dosing 54 Patrick W. Serruys 54 stem cell engraftment 54 intravesical therapy 54 Belldegrun 54 colorectal cancer liver metastases 54 vidofludimus 54 clinically localized prostate 54 Hakon Hakonarson 54 PROCHYMAL 54 intact parathyroid hormone 54 disease progression 54 extracapsular extension 54 VADT 54 Fred Kavalier 54 postoperative atrial fibrillation 54 ProSavin 54 Lorianne Masuoka MD 54 preserved ejection fraction 54 viral kinetics 54 obstructive coronary artery 54 sleeve lobectomy 54 azacitidine 54 plasma pharmacokinetics 54 pediatric malignancies 54 contralateral breast 54 CEACAM1 54 liver transplant recipients 54 5-fluorouracil/leucovorin 54 beta blocker therapy 54 Myerburg 54 WT1 54 anti angiogenic therapy 54 Tschöp 54 methotrexate monotherapy 54 epithelial ovarian cancer 54 Ruschitzka 54 HBeAg seroconversion 54 Karumanchi 54 postoperative delirium 54 lung fibrosis 54 BRAF V# mutation 54 poorer prognosis 54 Dawn Hershman 54 neoadjuvant chemotherapy 54 prolongs survival 54 IV malignant melanoma 54 hyperphenylalaninemia HPA due 54 androgen deprivation 54 Nir Barzilai 54 nonsmall cell lung cancer 54 abiraterone acetate 54 ADPKD 54 locoregional recurrence 54 allogeneic HSCT 54 TRAIL induced apoptosis 54 platinum refractory 54 sentinel lymph node biopsy 54 KRAS status 54 multivariable Cox 54 mutated KRAS 54 cranial irradiation 54 VTE prophylaxis 54 PTPN# 54 Clinical Antipsychotic Trials 54 Nigrovic 54 UGT#A# * 54 epithelial tumors 54 CIMZIA TM certolizumab pegol 54 clonogenic 54 DXL# 54 paclitaxel eluting stents 54 preoperative PSA 54 detecting precancerous 54 SERCA2a 54 secondary hyperparathyroidism 54 ispinesib administered 54 subcutaneous PRO 54 Mary Ann Peberdy 54 surrogate endpoint 54 underlying pathophysiology 54 elotuzumab 54 macroalbuminuria 54 Shlipak 54 Sudhir Agrawal D.Phil 54 estimated GFR 54 standard chemotherapy regimen 54 locoregional 54 thromboembolic complications 54 cyclophosphamide chemotherapy 54 Femara letrozole 54 relapsing MS 54 therapeutic armamentarium 54 Steven R. Deitcher 54 epigenetic therapies 54 GRNCM1 54 thrombophilia 54 TACI Ig 54 LHRH receptor positive 54 choroidal vasculopathy 54 platelet reactivity 54 Wolf Reik 54 chemopreventive agent 54 renal transplantation 54 ganetespib 54 advanced adenomas 54 aldosterone antagonists 54 predictive biomarkers 54 Jon Kar Zubieta 54 Matthew Meyerson 54 El Deiry 54 acute STEMI 54 pharmacodynamic PD 54 Leydig cell 54 fulvestrant 54 nephron sparing surgery 54 multiple myeloma MM 53 refractory NSCLC 53 immunopathology 53 diagnostic biomarker 53 RRMS patients 53 estrogen receptor ER 53 AGILECT R 53 localized renal 53 Phase #/#a 53 NSTE ACS 53 pharmacokinetic PK profile 53 dyskeratosis congenita 53 pT3 53 BCIRG 53 Anna Taddio 53 subclinical hypothyroidism 53 HBeAg negative 53 mg/m2 cohort 53 ErbB2 positive 53 independent prognostic marker 53 Viral load 53 PSADT 53 APOPTONE 53 thrombolytic therapy 53 Novartis Zometa 53 CMV disease 53 p# activation 53 PKCi 53 MDRD equation 53 eprotirome 53 Zolopa 53 granulocyte 53 chlamydial infection 53 histological subtype 53 Leon Flicker 53 cediranib 53 TroVax 53 Monique MB Breteler 53 micrometastasis 53 pertuzumab 53 GVAX 53 ALND 53 Liver transplantation 53 carotid IMT 53 gastric atrophy 53 Cloretazine ® 53 Elocalcitol 53 neoadjuvant treatment 53 recurrent metastatic 53 Telintra 53 metaglidasen 53 receptor tyrosine kinase inhibitor 53 IV NSCLC 53 basal cell nevus syndrome 53 nodal metastases 53 ENDEAVOR III 53 standard chemotherapy regimens 53 sustained virologic response 53 APOE e4 53 mTOR inhibition 53 cytoreductive nephrectomy 53 baseline HbA1c 53 George D. Yancopoulos 53 masitinib 53 stage IIIB IV 53 mutant KRAS 53 CYT# potent vascular disrupting 53 compound INCB# 53 microalbuminuria 53 curative therapy 53 CIN3 53 graft dysfunction 53 adverse perinatal 53 MammaPrint R 53 spontaneous regression 53 paricalcitol 53 taxane therapy 53 adrenalectomy 53 postoperative complication 53 idarubicin 53 renal carcinoma 53 HNSCC 53 CA9 SCAN 53 abiraterone 53 pamidronate 53 NNRTI resistance 53 LymphoStat B belimumab 53 untreated OSA 53 neuroblastoma tumors 53 Rectal cancer 53 Akshay Vaishnaw MD Ph.D. 53 PLX STROKE targeting 53 iniparib 53 dose cohort 53 pulmonary metastasis 53 diabetes mellitus DM 53 baseline LDH 53 familial pancreatic cancer 53 INCB# [003] 53 Cloretazine 53 lumiliximab 53 cangrelor 53 Teriflunomide 53 tesmilifene 53 HIV uninfected 53 BARACLUDE ® 53 Ocrelizumab 53 tipranavir 53 SLNB 53 NEUVENGE 53 refractory ALCL 53 corrected QT interval 53 thyroglobulin 53 cisplatin resistant 53 hepatic lesions 53 ACCEDE 53 inecalcitol 53 HbF 53 endocrine therapy 53 tumor subtype 53 VIDAZA ® 53 PSA nadir 53 nonmetastatic breast cancer 53 rALLy trial 53 HGS ETR2 53 virologic 53 randomized Phase 2b 53 Mihai Gheorghiade MD 53 Van Hemelrijck 53 CYP#C# genotype 53 glufosfamide 53 XmAb# 53 Joseph Loscalzo 53 ThGRF 53 response CCyR 53 neoadjuvant therapy 53 lipid lowering therapy 53 Gleevec resistant 53 cancer mCRC 53 Circulating tumor cells 53 EGFR mutations 53 ruxolitinib 53 oral clodronate 53 parkinsonian symptoms 53 biopsy Gleason 53 antithrombotic therapy 53 Kaklamani 53 colorectal tumor 53 lactate dehydrogenase 53 HGS# 53 TTF Therapy 53 IV bisphosphonates 53 seropositivity 53 R#/MEM # 53 pazopanib 53 EGFR TKI 53 D dimer 53 fibrotic disease 53 ImmuKnow 53 transfusion syndrome 53 pretest probability 53 Aggrastat ® tirofiban hydrochloride 53 relapsed multiple myeloma 53 histologically proven 53 hepatocellular carcinoma 53 surgically resectable 53 fibrinolysis 53 randomized multicenter trial 53 noninferiority 53 Univariate analysis 53 distant metastases 53 Tim Coughlin MAusIMM 53 XL# administered orally 53 PTK# 53 tumor subtypes 53 CMV vaccine 53 irinotecan chemotherapy 53 abnormal glucose tolerance 53 demonstrated antitumor activity 53 Vlachopoulos 53 cART 53 underwent liver transplantation 53 leukemia ALL 53 MitraClip device 53 blastic phase 53 ROCKET AF 53 multifactorial disease 53 HIV tropism 53 mechanically ventilated patients 53 prognostic indicator 53 PROSTVAC TM 53 talabostat 53 hemodynamically stable 53 neurocognitive function 53 Violari 53 resistant ovarian cancer 53 neoadjuvant 53 ECOG 53 cardiac dysfunction 53 PDE7B 53 biochemical abnormalities 53 SYMMETRY trial 53 overt nephropathy 53 Faslodex 53 INCB# [001] 53 Michael H. Tardugno 53 darapladib 53 proliferative retinopathy 53 pro angiogenic 53 NLX P# 53 Hilakivi Clarke 53 Dorry L. Segev 53 preclinically 53 dose proportionality 53 ponatinib 53 colorectal liver metastases 53 Dasatinib 53 oncogenesis 53 OMAPRO 53 adjuvant therapies 53 Kemal Malik 53 ACCORD Eye 53 reinfarction 53 cytoreduction 53 HuMax CD# 53 ICD therapy 53 Michele Heisler 53 gastric adenocarcinoma 53 SSc 53 Dr. Rivella 53 inhibit metastasis 53 polyp recurrence 53 caspofungin 52 Kristine Yaffe MD 52 Panzem R NCD 52 Lisa Mosconi 52 liver histology 52 Stephen Freedland 52 Akt activation 52 childhood acute lymphoblastic 52 basal cell carcinoma BCC 52 HbA1C 52 ventricular dysfunction 52 Jeremy Nathans 52 T1c 52 pharmacokinetic PK study 52 Tobias Kurth 52 Kinoid 52 null responder 52 basal bolus regimen 52 androgen suppression therapy 52 ReN# 52 R# #mg BID 52 Pischon 52 CTEPH 52 chemoradiotherapy 52 hemoglobin A1c HbA1c 52 dose escalation phase 52 adjuvant systemic 52 prospective longitudinal 52 percutaneous biopsy 52 TEMSO 52 Halaven 52 Campath alemtuzumab 52 HGS ETR1 52 clinically meaningful differences 52 coagulation abnormalities 52 CLORETAZINE TM VNP#M 52 EORTC 52 subthreshold depression 52 multivariate logistic regression 52 lymph node involvement 52 inhaled iloprost 52 immunosuppressive medication 52 IGFBP 3 52 chemosensitivity 52 Lymph node 52 virologic suppression 52 EUS FNA 52 therapeutic regimens 52 F FDG PET 52 Kaplan Meier curve 52 ASCUS 52 NAbs 52 hematologic malignancy 52 Demark Wahnefried 52 ZNF# 52 Zolinza 52 satraplatin Phase 52 lintuzumab 52 morphometric vertebral fractures 52 Nanette Wenger 52 PNH patients 52 Mattias Linde 52 acute aortic dissection 52 Adjuvant therapy 52 biochemical recurrence 52 Phase Ib study 52 cTnI 52 recurrent VTE 52 stage IIIb IV 52 TNF antagonist 52 ependymoma 52 atherosclerotic renal artery stenosis 52 Amarenco 52 Bob Evani 52 apremilast 52 Cerfolio 52 CDK inhibitor 52 Radical prostatectomy 52 Hurthle cell 52 fondaparinux 52 pulmonary toxicity 52 percutaneous cryoablation 52 refractory acute myeloid 52 Renal Cell Carcinoma RCC 52 preterm newborns 52 Free Survival PFS 52 lupus nephritis 52 mapatumumab 52 Imatinib 52 myeloproliferative diseases 52 pre operatively 52 MALT lymphoma 52 interferon therapy 52 Ancoli Israel 52 CBLC# 52 relapsed GBM 52 A3 adenosine receptor 52 potentially modifiable 52 nonhereditary 52 CaP 52 bronchoalveolar lavage 52 clazosentan 52 HQK 52 cabazitaxel 52 Winkelmayer 52 virologic responses 52 antiplatelet therapy 52 IFN γ 52 radical cystectomy 52 Tavocept 52 pathophysiological mechanisms 52 decompressive surgery 52 tirofiban 52 postoperative mortality 52 Hematologic 52 histopathologic examination 52 NATRECOR ® 52 oral ridaforolimus 52 curative resection 52 risk stratification 52 clinical pharmacology studies 52 chemoresistant 52 adjuvant therapy 52 recurrent miscarriage 52 lymph node metastasis 52 telomerase inhibition 52 Syrjala 52 anthracycline containing 52 CMV reactivation 52 limiting generalizability 52 OncoVEX GM CSF 52 BRCA carriers 52 TURBT 52 preintervention 52 CYP#C# [001] 52 oral anticoagulation 52 elevated triglyceride levels 52 Allovectin 7 ® 52 avosentan 52 stage IIIB 52 Nickolas Papadopoulos 52 Okunieff 52 IPAH 52 ONCONASE R 52 monoclonal gammopathy 52 coronary CTA 52 JAK2 inhibitor 52 radical nephrectomy 52 tipranavir r 52 SLN biopsy 52 renal allograft 52 ZOLINZA 52 antitumor effect 52 DHFR 52 nonalcoholic steatohepatitis 52 Stent thrombosis 52 Laquinimod 52 Tiganis 52 FTIs 52 sero positive 52 decompensated cirrhosis 52 acute lymphoblastic 52 antibody mediated 52 CRLX# 52 previously untreated follicular 52 Dose escalation 52 systolic dysfunction 52 Xelox 52 erythropoietic 52 TGFBR1 * 6A 52 Kuppermann 52 Lisofylline 52 ACTEMRA TM 52 grade cervical intraepithelial 52 allogeneic SCT 52 DCVax R Brain 52 gemcitabine carboplatin 52 Phase #b/#a 52 Tocosol Paclitaxel 52 Seewaldt 52 silent ischemia 52 kidney urologic 52 novel VDA molecule 52 clinicopathological features 52 Artificial pancreas 52 Dr. Pasinetti 52 oral talactoferrin 52 recurrent glioma 52 Randomized trials 52 NATRECOR R 52 budesonide MMX Phase III 52 non squamous histology 52 axillary dissection 52 invasive aspergillosis 52 Ezekowitz 52 MYCN amplification 52 John G. McHutchison 52 hypofractionated radiation 52 George Coukos 52 DNA methylation markers 52 FDG-PET/CT 52 subgroup analyzes 52 undergoing coronary angiography 52 StemEx R 52 CIB1 52 Alton Boynton 52 #mg dose [002] 52 aromatase inhibitor therapy 52 tumor resection 52 adjuvant radiotherapy 52 Elena Losina 52 SNP rs# [002] 52 hepatectomy 52 troponins 52 Acute renal failure 52 Hormone Refractory Prostate Cancer 52 antigen PSA 52 MADIT II 52 Afib 52 GAMMAGARD 52 peritoneal cancer 52 systemic ALCL 52 recurrent GBM 52 dosing cohort 52 anti angiogenic drugs 52 fluvastatin 52 Itopride 52 Debinski 52 Mr. Rosconi 52 unfavorable cytogenetics 52 p# inhibitor 52 invasive carcinoma 52 molecularly targeted therapies 52 Angela Genge 52 Pharmacokinetic studies 52 PROLARIS 52 secondary efficacy endpoint 52 radiographic outcomes 52 S#A# [002] 52 carotid stenosis 52 Advagraf 52 CCyR 52 stratify patients 52 postoperative AF 52 dasatinib Sprycel 52 HGPIN 52 periprosthetic infection 52 relapsed MCL 52 aleglitazar 52 KRAS mutation status 52 ADVEXIN efficacy 52 % CI #.#-#.# [007] 52 cardiac repolarization 52 MMSE score 52 castrate resistant 52 BMPR2 52 rALLy 52 El Sohemy 52 curative treatments 52 prognostic biomarkers 52 lactate dehydrogenase LDH 52 NOX E# 52 OPCAB 52 cannabinor 52 multivessel coronary artery 52 randomized Phase IIb 52 Karl Swedberg 52 Dr. Arie Belldegrun 52 metastatic bladder 52 multivariable analysis 52 LRP5 52 Chronic pancreatitis 52 ToGA 52 HER2 neu 52 Tomasz Beer 52 precursor lesions 52 Karolinska Institutet Stockholm Sweden 52 nilotinib 52 complete cytogenetic 52 leukemia AML 52 cardiac insufficiency 52 EndoTAG TM -1 52 Venous thromboembolism 52 allogenic stem cell 52 Ophena TM 52 panobinostat 52 multivariate analyzes 52 Phase Ib IIa 52 antiphospholipid antibodies 52 undergoing liver transplantation 52 nonsquamous 52 prelicensure 52 polyomavirus nephropathy 52 COPAXONE R 52 ATACAND 52 undergoing bariatric surgery 52 PLCO trial 52 % CI #.#-#.# [003] 52 Clusterin 52 maximally tolerated dose 52 SCD HeFT 52 virologic response 52 liver resection 52 Non inferiority 52 Kissela 52 CDH1 52 William Gradishar 52 hemoglobin A1c levels 52 hypercholesterolemic patients 52 metastatic HRPC 52 teriflunomide 52 postintervention 52 Angiotensin converting enzyme 52 Stephanie Studenski 52 rindopepimut 52 univariate analyzes 52 superficial bladder cancer